Minimal, measurable and molecular residual disease
In one sentence
Residual disease is cancer remaining after treatment; MRD describes small amounts sought with sensitive methods, whose meaning depends on the disease, specimen and assay.
The intuition
After clearing a garden, you may inspect the ground for roots too small to see from a distance. Different tools inspect different patches. A negative inspection says what that tool found in its patch, rather than proving the whole garden is empty.
The analogy has limits: an MRD assay may measure molecules or cell features, not directly count viable cancer cells. Its result is an inference with defined performance and clinical context.
How it works
MRD has several expansions. Minimal residual disease emphasizes small remaining amounts. Measurable residual disease, used in blood-cancer guidance, emphasizes the method's ability to detect them. Molecular residual disease often describes tumor-associated molecular signals after treatment, particularly blood circulating tumor DNA (ctDNA) in solid-tumor studies. Always check which meaning a paper uses.
In blood cancers, methods can examine characteristic cells by flow cytometry, or track molecular features in blood or bone marrow. In solid tumors, plasma assays may look for tumor-associated DNA variants or other features. Cell-frequency thresholds, molecular ratios and plasma detection rules are different quantities. A leukemia cutoff is not a breast-cancer plasma cutoff.
“Residual disease” on surgical pathology also has its own meaning: tissue can show remaining invasive cancer even if blood has no qualifying signal. Residual cancer burden measures a defined tissue endpoint. It is not interchangeable with a blood MRD call.
A positive molecular call can supply evidence consistent with remaining disease and can be associated with later recurrence in a studied setting. It does not reveal where the disease is, prove every detected molecule came from a currently living tumor cell, or guarantee recurrence. A negative call leaves sampling and analytical limits. Timing relative to treatment and specimen handling belong beside either result.
Why it matters in cancer
MRD can enrich a research cohort for higher recurrence risk. Whether changing treatment after that result helps requires separate clinical-utility evidence. Marker clearance is a measured endpoint; using it as a substitute for survival benefit requires validation in the intended setting.
How it is measured
| Assay-card item | Scope to keep attached |
|---|---|
| Measures / how | Disease-associated cells or molecular features, with an explicit method |
| Input and cost | Blood, marrow or another defined specimen; finite material and collection burden |
| Output / units | Cell percentage, molecular ratio, concentration or assay-defined positive/negative call |
| Thresholds | Method-, disease- and time-point-specific criteria; no universal MRD cutoff |
| Failure modes | Unrepresentative specimen, low input, unsuitable targets, background or collection artifacts |
| Cannot tell | Guaranteed cure, inevitable recurrence, location or benefit from a proposed intervention |
| Validation | Exact disease, treatment setting, specimen, timing and intended decision |
Common confusions
- MRD-negative does not mean “no cancer cell remains anywhere.”
- A plasma MRD result and a pathology result can differ because they observe different material.
- A prognostic association does not establish an MRD-triggered treatment strategy.
Try it
In a fictional study, a postoperative plasma test is negative but surgery shows residual invasive cancer. Must one test be wrong?
Answer: No. Pathology directly examined tissue at surgery; plasma testing sought a qualifying molecular signal in a later blood sample. Both can be valid within their scopes. Dates, specimen and assay limits must be reconciled before interpreting the pair.
Explain it back
What specimen and rule would you need before interpreting the words “MRD-negative”?
Takeaway
MRD is a method-bound residual-disease assessment, not a universal declaration of cure or a treatment instruction.
Related concepts
Sources and scope
Source check: October 10, 2026. Fictional exercise; expert and learner review remain pending.
- NCI definition of minimal residual disease — small residual amounts and sensitive testing.
- Heuser et al. 2021 ELN consensus — disease-specific methods, specimens, time points and reporting in acute myeloid leukemia; its thresholds are not transferred here.
- FDA 2024 circulating tumor DNA (ctDNA) drug-development guidance — solid-tumor prognostic, strategy and endpoint-validation questions.